Usual Adult Dose for Dermatitis

Cream/Ointment: Apply a thin film to affected area twice a day

Comments:

• Therapy should be discontinued when control is achieved.
• If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
• The safety and efficacy of drug use for longer than 4 weeks have not been established.

Use: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Usual Adult Dose for Eczema

Cream/Ointment: Apply a thin film to affected area twice a day

Comments:

• Therapy should be discontinued when control is achieved.
• If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
• The safety and efficacy of drug use for longer than 4 weeks have not been established.

Use: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Usual Adult Dose for Atopic Dermatitis

Cream: Apply a thin film to affected area once or twice a day
Ointment: Apply sparingly in a thin film twice a day
Lotion: Apply sparingly in a thin film to affected area once a day

Comments:

• Therapy should be discontinued when control is achieved.
• If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
• The safety and efficacy of drug use for longer than 4 weeks have not been established.

Use: Relief of the inflammatory and pruritic manifestations of atopic dermatitis

Usual Pediatric Dose for Dermatitis

3 months and older:
Cream/Ointment: Apply a thin film to affected area twice a day

Comments:

• The safety and efficacy of drug use for longer than 4 weeks in this population have not been established.
• If no improvement is seen within 2 weeks, a healthcare provider should be contacted.
• This topical drug should not be used with occlusive dressings or applied in the diaper area unless directed by a healthcare professional.

Use: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Usual Pediatric Dose for Eczema

3 months and older:
Cream/Ointment: Apply a thin film to affected area twice a day

Comments:

• The safety and efficacy of drug use for longer than 4 weeks in this population have not been established.
• If no improvement is seen within 2 weeks, a healthcare provider should be contacted.
• This topical drug should not be used with occlusive dressings or applied in the diaper area unless directed by a healthcare professional.

Use: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Usual Pediatric Dose for Atopic Dermatitis

3 months and older:
Cream: Apply a thin film to affected area once or twice a day
Ointment: Apply sparingly in a thin film twice a day
Lotion: Apply sparingly in a thin film to affected area once a day

Comments:

• The safety and efficacy of drug use for longer than 4 weeks in this population have not been established.
• If no improvement is seen within 2 weeks, a healthcare provider should be contacted.
• This topical drug should not be used with occlusive dressings or applied in the diaper area unless directed by a healthcare professional.

Use: Relief of the inflammatory and pruritic manifestations of atopic dermatitis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 3 months.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug should not be used on the face, groin, or axillae, unless directed by a healthcare professional.
• The treated area should not be bandaged, covered, or wrapped, as to be occlusive, unless directed by a healthcare provider.
• Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area.

Monitoring:

• Endocrine: HPA-axis suppression (Urinary free-cortisol test, ACTH-stimulation test)

Patient advice:

• Patients should report any signs of local adverse reactions, especially those that develop under occlusive dressings.